2/3
01:03 pm
ibrx
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX
2/2
07:13 am
ibrx
ImmunityBio Launches Phase 2 Chemotherapy-Free CAR-NK Cell Therapy Trial with ANKTIVA® (ResQ215B) in Indolent Lymphomas [Yahoo! Finance]
Low
Report
ImmunityBio Launches Phase 2 Chemotherapy-Free CAR-NK Cell Therapy Trial with ANKTIVA® (ResQ215B) in Indolent Lymphomas [Yahoo! Finance]
2/2
07:00 am
ibrx
ImmunityBio Launches Phase 2 Chemotherapy-Free CAR-NK Cell Therapy Trial with ANKTIVA® (ResQ215B) in Indolent Lymphomas
Low
Report
ImmunityBio Launches Phase 2 Chemotherapy-Free CAR-NK Cell Therapy Trial with ANKTIVA® (ResQ215B) in Indolent Lymphomas
1/29
10:00 am
ibrx
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX
1/27
12:40 pm
ibrx
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX
1/26
08:04 am
ibrx
ImmunityBio (NASDAQ:IBRX) had its price target raised by analysts at HC Wainwright from $8.00 to $10.00. They now have a "buy" rating on the stock.
Medium
Report
ImmunityBio (NASDAQ:IBRX) had its price target raised by analysts at HC Wainwright from $8.00 to $10.00. They now have a "buy" rating on the stock.
1/25
02:02 am
ibrx
Stock Market Today, Jan. 23: ImmunityBio Falls After Gaining Over 200% in a Month [Yahoo! Finance]
Medium
Report
Stock Market Today, Jan. 23: ImmunityBio Falls After Gaining Over 200% in a Month [Yahoo! Finance]
1/23
07:00 am
ibrx
ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy
High
Report
ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy
1/22
07:02 pm
ibrx
ImmunityBio (NASDAQ:IBRX) had its "buy" rating reaffirmed by analysts at BTIG Research.
High
Report
ImmunityBio (NASDAQ:IBRX) had its "buy" rating reaffirmed by analysts at BTIG Research.
1/22
09:41 am
ibrx
Jim Cramer on ImmunityBio: “I Really Think That You Have to Take Profits in Some of That” [Yahoo! Finance]
Medium
Report
Jim Cramer on ImmunityBio: “I Really Think That You Have to Take Profits in Some of That” [Yahoo! Finance]
1/21
06:23 pm
ibrx
Stock Market Today, Jan. 21: ImmunityBio Rises Again As Short-Sellers Face Losses [Yahoo! Finance]
Medium
Report
Stock Market Today, Jan. 21: ImmunityBio Rises Again As Short-Sellers Face Losses [Yahoo! Finance]
1/20
07:46 pm
ibrx
Lightning Round: Shell is ‘just an ok oil company', says Jim Cramer [CNBC]
Medium
Report
Lightning Round: Shell is ‘just an ok oil company', says Jim Cramer [CNBC]
1/20
10:26 am
ibrx
ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA® in BCG-Unresponsive Papillary Bladder Cancer [Yahoo! Finance]
Low
Report
ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA® in BCG-Unresponsive Papillary Bladder Cancer [Yahoo! Finance]
1/20
08:02 am
ibrx
ImmunityBio (NASDAQ:IBRX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $24.00 price target on the stock.
Low
Report
ImmunityBio (NASDAQ:IBRX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $24.00 price target on the stock.
1/20
07:34 am
ibrx
S&P 500 Futures Drop in Premarket Trading; ImmunityBio, Enlight Renewable Energy Lead [Barron's]
Low
Report
S&P 500 Futures Drop in Premarket Trading; ImmunityBio, Enlight Renewable Energy Lead [Barron's]
1/20
07:17 am
ibrx
ImmunityBio (NASDAQ:IBRX) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Low
Report
ImmunityBio (NASDAQ:IBRX) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
1/20
04:00 am
ibrx
ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA® in BCG-Unresponsive Papillary Bladder Cancer
High
Report
ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA® in BCG-Unresponsive Papillary Bladder Cancer
1/19
09:31 pm
ibrx
ImmunityBio (IBRX) Soars 137% on Expansion Plan, Clinical Results [Yahoo! Finance]
High
Report
ImmunityBio (IBRX) Soars 137% on Expansion Plan, Clinical Results [Yahoo! Finance]
1/19
05:31 pm
ibrx
ImmunityBio, Inc. (IBRX): A Bull Case Theory [Yahoo! Finance]
High
Report
ImmunityBio, Inc. (IBRX): A Bull Case Theory [Yahoo! Finance]
1/19
07:30 am
ibrx
ImmunityBio's allogeneic CD19 cell therapy shows complete response beyond 15 months [Yahoo! Finance]
Medium
Report
ImmunityBio's allogeneic CD19 cell therapy shows complete response beyond 15 months [Yahoo! Finance]
1/16
05:52 pm
ibrx
ImmunityBio: Making Strides, But Beware The Hype (Rating Downgrade) [Seeking Alpha]
High
Report
ImmunityBio: Making Strides, But Beware The Hype (Rating Downgrade) [Seeking Alpha]
1/16
02:23 pm
ibrx
Why ImmunityBio Stock Is Skyrocketing Again Today [Yahoo! Finance]
Medium
Report
Why ImmunityBio Stock Is Skyrocketing Again Today [Yahoo! Finance]
1/16
11:51 am
ibrx
ImmunityBio (IBRX) Extends Gains to 10th Day on 700% Anktiva Sales Jump; Time to Book Profits? [Yahoo! Finance]
Neutral
Report
ImmunityBio (IBRX) Extends Gains to 10th Day on 700% Anktiva Sales Jump; Time to Book Profits? [Yahoo! Finance]
1/16
09:34 am
ibrx
Ford & BYD reportedly in talks to partner, PNC rises on earnings [Yahoo! Finance Canada]
Low
Report
Ford & BYD reportedly in talks to partner, PNC rises on earnings [Yahoo! Finance Canada]
1/16
08:27 am
ibrx
ImmunityBio Says Potential Lymphoma Therapy Extends Complete Response to 15 Months [Yahoo! Finance]
Medium
Report
ImmunityBio Says Potential Lymphoma Therapy Extends Complete Response to 15 Months [Yahoo! Finance]